Google DeepMind CEO Demis Hassabis said AI-designed drugs could significantly reduce traditional development timelines. He outlined the vision of Isomorphic Labs to accelerate pharmaceutical innovation. Hassabis said AI could transform research by predicting molecular structures and identifying treatments faster. The initiative aims to replace lengthy manual discovery processes. The announcement reflects growing investment in AI-powered healthcare research and drug development.
Google DeepMind CEO Demis Hassabis said AI-designed drugs could significantly reduce traditional development timelines. He outlined the vision of Isomorphic Labs to accelerate pharmaceutical innovation. Hassabis said AI could transform research by predicting molecular structures and identifying treatments faster. The initiative aims to replace lengthy manual discovery processes. The announcement reflects growing investment in AI-powered healthcare research and drug development.